Chromoblastomycosis stands as a persistent and neglected subcutaneous mycosis, induced by various fungi species belonging to the Herpotrichiellaceae family. Our company spearheads innovation in the domain of infectious diseases such as chromoblastomycosis, delivering a holistic spectrum of services tailored to cater to the requisites of researchers and scientists delving into this specialized field.
Overview of Chromoblastomycosis
This chronic fungal infection, chromoblastomycosis, infiltrates the skin and subcutaneous tissues, orchestrated by fungi strains like Fonsecaea pedrosoi, Cladophialophora carrionii, and Phialophora verrucosa hailing from the Herpotrichiellaceae lineage. Exhibiting a striking propensity for tropical and subtropical climates, with prevalence figures of 1:6800 in Madagascar and 1:196,000 in Brazil, chromoblastomycosis manifests in various forms including nodular, tumoral type, verrucous, plaque, and cicatricial.
Fig.1 Acquired immune responses and outcome of chromoblastomycosis. (Passero, L. F. D., et al., 2021)
Pathogenesis of Chromoblastomycosis
The etiology of chromoblastomycosis entails the incisive introduction of fungal spores into the skin, resulting in the formation of chronic granulomatous lesions. The chronic nature of the infection is attributed to the ability of these fungi to evade the immune system and form biofilms, making therapy challenging. A few days after infection, the fungal entity transforms muriform cells ensconced within phagocytic cells. These muriform or sclerotic cells are characterized by their rounded morphology, multicellular septation, and pigmentation.
Fig.2 A prototype scheme of induction of innate immunity in chromoblastomycosis. (Passero, L. F. D., et al., 2021)
Vaccine and Therapeutic Development for Chromoblastomycosis
| Types |
Names |
Mechanism of Action |
Targets |
Research Phase |
| DNA Vaccine |
DNA-hsp65 vaccine |
Reduction in NO production |
Hsp65 |
Preclinical research |
| Small molecule drug |
Amphotericin B |
Formed channels that cause leakage of fungal cell components and death |
Ergosterol |
Approved |
| Itraconazole |
Inhibit the demethylation of lanosterol and consequently the production of fungal ergosterol |
CYP51A1 |
Approved |
| Acitretin |
Inhibit endothelial growth and angiogenesis |
RARs |
Approved |
| Imiquimod |
Stimulate the immune response |
TLR 7/8 |
Approved |
| Ajoene |
Inhibit the biosynthesis of phosphatidylcholine, a cell membrane component |
/ |
Clinical research |
| Monoclonal antibody |
Mab anti-GlcCer |
Fungistatic and fungicidal activities |
GlcCer |
Preclinical research |
| Purified antibodies anti-Melanin |
Fungicidal activities |
Melanin |
Preclinical research |
| Photodynamic therapy |
Methylene blue-LED |
Product reactive oxygen species and other reactive molecules |
/ |
Clinical research |
Our Services
Leveraging an advanced platform tailored for disease modeling, vaccine development, and therapeutic exploration, our company provides a conduit to an assortment of tools, technologies, and specialized knowledge requisite for elucidating pathogenesis, devising therapy modalities, and exploring potential interventions for infections like chromoblastomycosis.
Featured Services for Chromoblastomycosis
Infectious Disease Models
- CD8 KO model of Fonsecaea pedrosoi infection
- IL-10 KO model of Fonsecaea pedrosoi infection
- CD4 KO model of Fonsecaea pedrosoi infection
- Athymic nude mice model of C. carrionii infection
- Others
Why Choose Us
With a dedicated focus on infectious diseases, we provide a unique advantage by combining cutting-edge research support, access to state-of-the-art laboratory facilities, expert consultation services, and a wide array of resources essential for studying and combating these complex diseases effectively.
If you are interested in our service, we encourage you to contact us for more information tailored to your specific research needs.
References
- Passero, Luiz Felipe Domingues et al. "Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis." Journal of immunology research (2021): 9742832.
- Breda, Leandro C D et al. "Immune Sensing and Potential Immunotherapeutic Approaches to Control Chromoblastomycosis." Journal of fungi (Basel, Switzerland) 7.1 (2020): 3.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
